



Appendix 4

This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors.

Appendix to: Chew DP, French J, Briffa TG, et al. Acute coronary syndrome care across Australia and New Zealand: the SNAPSHOT ACS study. *Med J Aust* 2013; online first 17 May. doi: 10.5694/mja12.11854.

Appendix 4 Table 3: In-hospital care among patients with ACS stratified by Health Jurisdiction

	Total (n=2,365)	NZ (n=532)	NSW/ACT (n=550)	QLD (n=366)	VIC (n=468)	WA (n=237)	SA (n=139)	NT/TAS (n=73)	P value
Investigations									
Exercise Test (n,%)	170 (7.2%)	89 (16.7%)	30 (5.5%)	22 (6.0%)	7 (1.5%)	6 (2.5%)	10 (7.2%)	6 (8.2%)	<0.001
Echocardiogram (n,%)	872 (36.9%)	210 (39.5%)	220 (40.0%)	154 (42.1%)	157 (33.6%)	71 (30.0%)	43 (30.9%)	17 (23.3%)	0.001
Stress Echocardiogram (n,%)	39 (1.7%)	4 (0.8%)	13 (2.4%)	8 (2.2%)	2 (0.4%)	8 (3.4%)	1 (0.7%)	3 (4.1%)	0.009
Stress Nuclear Study (n,%)	65 (2.8%)	1 (0.2%)	16 (2.9%)	6 (1.6%)	23 (4.9%)	11 (4.6%)	7 (5.0%)	1 (1.4%)	<0.001
CT Coronary Angiogram (n, %)	90 (3.8%)	23 (4.3%)	24 (4.4%)	21 (5.7%)	6 (1.3%)	12 (5.1%)	4 (2.9%)	0 (0%)	0.009
Coronary Angiogram (n,%)	1341 (56.7%)	285 (53.6%)	328 (59.6%)	203 (55.5%)	271 (57.9%)	143 (60.3%)	65 (46.8%)	46 (63.0%)	0.05
In-hospital Pharmacotherapies									
Aspirin (n, %)	2204 (99.2%)	504 (94.7%)	503 (91.5%)	345 (94.3%)	442 (94.4%)	222 (93.7%)	118 (84.9%)	70 (95.9%)	0.001
Unfractionated Heparin (n, %)	877 (37.1%)	204 (38.4%)	220 (40.0%)	108 (29.5%)	196 (41.9%)	84 (35.4%)	49 (35.3%)	16 (21.9%)	0.001

LMWH (n, %)	1236 (52.2%)	349 (65.6%)	225 (40.9%)	216 (59.0%)	246 (52.6%)	118 (49.8%)	35 (25.2%)	47 (64.4%)	<0.001
GP IIb/IIIa antagonist (n, %)	191 (8.1%)	39 (7.3%)	51 (9.3%)	17 (4.7%)	51 (10.9%)	24 (10.1%)	2 (1.4%)	7 (9.6%)	0.001
Revascularization and Pharmacotherapies at discharge*									
PCI (n, %)	743 (31.4%)	166 (31.2%)	192 (34.9%)	109 (29.8%)	139 (29.7%)	86 (36.3%)	29 (20.9%)	22 (30.1%)	0.03
CABG (n, %)	158 (6.7%)	30 (5.6%)	49 (8.9%)	25 (6.9%)	35 (7.5%)	10 (4.2%)	7 (5.0%)	2 (2.7%)	0.10
Aspirin (n,%)	2006 (87.2%)	469 (91.1%)	440 (82.4%)	322 (89.4%)	402 (89.3%)	205 (88.7%)	104 (75.9%)	64 (88.9%)	<0.001
Other Anti-platelet agents (n,%)	1451 (63.1%)	355 (68.9%)	316 (59.2%)	231 (64.2%)	250 (55.6%)	172 (74.5%)	76 (55.4%)	51 (70.8%)	<0.001
Statins (n,%)	1901 (82.7%)	439 (85.2%)	408 (76.4%)	311 (86.3%)	384 (85.3%)	201 (87.0%)	100 (73.0%)	58 (80.6%)	<0.001
Beta-blockers (n,%)	1640 (71.3%)	400 (77.7%)	354 (66.3%)	257 (71.4%)	334 (74.2%)	182 (78.8%)	61 (44.5%)	52 (72.2%)	<0.001
ACE-1/ARB (n,%)	1506 (65.5%)	319 (61.9%)	322 (60.3%)	243 (67.5%)	306 (68.0%)	176 (76.2%)	90 (66.7%)	50 (69.4%)	0.001
Secondary Prevention Advice*									

In-hospital Prevention Advice (n,%)	962 (41.8%)	258 (50.1%)	179 (33.5%)	184 (51.2%)	197 (43.8%)	88 (38.1%)	32 (23.4%)	24 (33.3%)	<0.001
Smoking cessation Advice** (n,%)	301 (69.5%)	72 (84.7%)	62 (63.9%)	55 (79.7%)	63 (65.0%)	26 (60.5%)	9 (42.9%)	14 (66.7%)	0.001
Physical Activity Advice (n,%)	988 (43.0%)	213 (41.4%)	216 (40.5%)	202 (56.4%)	194 (43.1%)	98 (42.4%)	27 (19.7%)	37 (51.4%)	<0.001
Dietary Modification Advice (n,%)	831 (36.1%)	162 (31.5%)	163 (30.5%)	188 (52.2%)	179 (39.8%)	86 (37.2%)	17 (12.4%)	36 (50.0%)	<0.001
Depression Screening (n,%)	228 (9.9%)	65 (12.6%)	62 (11.6%)	54 (15.0%)	17 (3.8%)	15 (6.5%)	7 (5.1%)	8 (11.1%)	<0.001
Outpatient Prevention Referral (n,%)	1065 (46.3%)	211 (41.0%)	276 (51.7%)	171 (47.5%)	23 (52.2%)	104 (45.0%)	28 (21.2%)	39 (54.2%)	<0.001

*Among patients discharged alive. ** Among current smokers discharged alive.

LMWH= Low Molecular Weight Heparin; GP =Glycoprotein, PCI= percutaneous coronary intervention; CABG= Coronary artery bypass grafting; ACE-I= Angiotensin Converting Enzyme Inhibitor; ARB= Angiotensin Receptor Blocker;